HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frank Loganzo Selected Research

HTI-286

5/2005Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.
11/2004Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
10/2004Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
3/2004Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents.
11/2003Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules.
4/2003HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frank Loganzo Research Topics

Disease

24Neoplasms (Cancer)
01/2022 - 04/2003
4Breast Neoplasms (Breast Cancer)
10/2020 - 10/2004
2Carcinoma (Carcinomatosis)
11/2004 - 04/2003
1Leukemia
01/2021
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021
1Lung Neoplasms (Lung Cancer)
10/2020
1Stomach Neoplasms (Stomach Cancer)
01/2017
1Communicable Diseases (Infectious Diseases)
07/2016
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2004
1Necrosis
03/2004

Drug/Important Bio-Agent (IBA)

10Immunoconjugates (Immunoconjugate)IBA
01/2022 - 04/2015
6Member 1 Subfamily B ATP Binding Cassette TransporterIBA
02/2006 - 04/2003
6HTI-286IBA
05/2005 - 04/2003
4auristatinIBA
01/2022 - 12/2014
4Pharmaceutical PreparationsIBA
10/2020 - 10/2004
4Paclitaxel (Taxol)FDA LinkGeneric
02/2006 - 04/2003
3Cytotoxins (Cytolysins)IBA
11/2021 - 11/2014
3AntigensIBA
01/2021 - 04/2015
3Ado-Trastuzumab EmtansineIBA
10/2020 - 01/2017
2Cysteine (L-Cysteine)FDA Link
10/2020 - 01/2017
2Proteins (Proteins, Gene)FDA Link
04/2015 - 10/2004
2hemiasterlinIBA
05/2005 - 11/2004
2Docetaxel (Taxotere)FDA Link
03/2004 - 09/2003
2Taxoids (Taxanes)IBA
03/2004 - 09/2003
2MAC321IBA
03/2004 - 09/2003
1Extracellular Matrix ProteinsIBA
01/2022
1Biomarkers (Surrogate Marker)IBA
01/2022
1Fibronectins (Fibronectin)IBA
01/2022
1Histones (Histone)IBA
01/2022
1RNA Splicing FactorsIBA
11/2021
1RNA (Ribonucleic Acid)IBA
11/2021
1RNA Precursors (Precursor, mRNA)IBA
11/2021
1Brentuximab VedotinIBA
01/2017
1Immune Checkpoint InhibitorsIBA
02/2016
1Trastuzumab (Herceptin)FDA Link
04/2015
1Peptides (Polypeptides)IBA
12/2014
1Biological ProductsIBA
06/2013
1CL 347099IBA
02/2006
1TubulinIBA
11/2004
1multidrug resistance-associated protein 1IBA
10/2004
1HTI 042IBA
09/2004
1Contrast MediaIBA
03/2004
1Vinorelbine (Navelbine)FDA LinkGeneric
03/2004
1Vincristine (Oncovin)FDA LinkGeneric
04/2003

Therapy/Procedure

9Therapeutics
01/2022 - 11/2004
2Drug Therapy (Chemotherapy)
08/2014 - 12/2005